WHO prequalifies first generic active ingredient for hepatitis C medicines
M
On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir.
4th Invitation to manufacturers and suppliers of medicinal products for treatment of hepatitis B and C to submit an expression of interest for product evaluation (EOI)
M
The following products were added:
- Sofosbuvir/Velpatasvir tablet 400mg/100mg
- Velpatasvir tablet 100mg